$ARVN

Cacace Angela M sold $20K of ARVN

Cacace Angela M (Chief Scientific Officer) sold 2,576 shares of ARVINAS, INC. (ARVN) at $7.60 on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cacace Angela M
Published Jun 18, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ARVN
Neutral
high confidence
Mentioned
$ARVN
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARVNNeutralLow
01

Why it matters

The filing documents an officer’s scheduled open-market sale; it does not include guidance, trial results, contracts, or enforcement actions.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure limits fundamental interpretation.

03

What to watch

Insider sales can be misread; traders should check whether there are concurrent buys, option exercises, or other filings around the same period before inferring direction.

Relevance 2/10Novelty 2/10Timing: filed 2026-06-18, transaction dated 2026-06-17

Background

The article is an SEC Form 4 insider transaction disclosure for ARVINAS, Inc.

Company-level read

Ticker impact

$ARVNNeutralHigh confidence
Context

ARVINAS CSO Angela M. Cacace sold 2,576 shares in an open-market transaction at $7.5950 on 2026-06-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any impact would be short-lived sentiment noise.

Evidence & confidence

The disclosure is an insider open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operational, financial, or regulatory information.

Market effects

No clear sector read-through from a single routine 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • ARVINAS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Angela M. Cacace

    Chief Scientific Officer who sold shares under a 10b5-1 plan.

Related articles

$ARVNMedAI 8/10

Why is Arvinas stock surging today?

Arvinas shares rose 13.2% after the company reported Q2 2026 results before the open. EPS was $2.58 versus a forecast loss of $0.38, and revenue was $249.7 million versus $58.61 million expected, including licensing and milestone items tied to VEPPANU and Rigel. Management cited VEPPANU approval, upcoming Phase 1 data, and a cash runway into H2 2028.

$ARVNMed

ARVINAS, INC. (ARVN): Results of Operations and Financial Condition

ARVINAS, INC. (ARVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update – Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfull

$GLUEMedAI 9/10

Molecular glue is shaping up to be the next billion-dollar cancer breakthrough

Bloomberg reports that Revolution Medicines’ daraxonrasib, a “molecular glue” drug, doubled median survival in aggressive pancreatic cancer from 6.7 to 13.2 months, with full phase 3 results expected at a Chicago conference. The success has spurred dealmaking and partnerships, including Monte Rosa’s potential $10B+ pacts with Novartis and Roche and J&J’s $3.05B Halda acquisition.